Pharmacotherapy and gambling disorder: a narrative review

References

• Shaffer HJ, Hall MN, Bilt JV. Estimating the prevalence of disordered gambling behavior in the United States and Canada: a research synthesis. Am J Public Health. 1999;89(9):1369–76. doi:10.2105/ajph.89.9.1369.
   PubMed Web of Science ®Google Scholar
• Blum AW, Grant JE. Behavioral addictions and criminal responsibility. J Am Acad Psychiatry Law. 2017;45(4):464–71. http://jaapl.org/content/45/4/464.long (accessed 24.09.21).
   PubMed Web of Science ®Google Scholar
• Morasco BJ, Petry NM. Gambling problems and health functioning in individuals receiving disability. Disabil Rehabil. 2006;28(10):619–23. doi:10.1080/09638280500242507.
   PubMed Web of Science ®Google Scholar
• APA. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arksey, H., O’Malley, L., 2005. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2013;8(1):19–32. doi:10.1080/1364557032000119616.
   Google Scholar
• Blanco C, Moreyra P, Nunes EV, Sáiz-Ruiz J, Ibáñez A. Pathological gambling: addiction or compulsion? Semin Clin Neuropsychiatry. 2001;6(3):167–76. doi:10.1053/scnp.2001.22921.
   PubMedGoogle Scholar
• Potenza MN. The neurobiology of pathological gambling. Semin Clin Neuropsychiatry. 2001;6(3):217–26. PMID: 11447573.
   PubMedGoogle Scholar
• DeCaria CM, Hollander E, Grossman R, Wong CM, Mosovich SA, Cherkasky S. Diagnosis, neurobiology, and treatment of pathological gambling. J Clin Psychiatry. 1996;57 Suppl 8:80–3. discussion 83:–4.
   PubMed Web of Science ®Google Scholar
• Calado F, Griffiths MD. Problem gambling worldwide: an update and systematic review of empirical research (2000–2015). J Behav Addict. 2016;5(4):592–613. doi:10.1556/2006.5.2016.073.
   PubMed Web of Science ®Google Scholar
• Potenza MN, Balodis IM, Derevensky J, Grant JE, Petry NM, Verdejo-Garcia A, Yip SW. Gambling disorder. Nat Rev Dis Primers. 2019;5(1):51. doi:10.1038/s41572-019-0099-7.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Hwang I, LaBrie R, Petukhova M, Sampson NA, Winters KC, Shaffer HJ. DSM-IV pathological gambling in the National Comorbidity Survey Replication. Psychol Med. 2008;38(9):1351–60. doi:10.1017/s0033291708002900.
   PubMed Web of Science ®Google Scholar
• ReadCube Papers. version 4.14.6, 2023. Papers, https://www.papersapp.com/
   Google Scholar
• Bartley CA, Bloch MH. Meta-analysis: pharmacological treatment of pathological gambling. Expert Rev. Neurother. 2013;13(8):887–94. doi:10.1586/14737175.2013.814938.
   PubMed Web of Science ®Google Scholar
• Goslar M, Leibetseder M, Muench HM, Hofmann SG, Laireiter A-R. Pharmacological treatments for disordered gambling: a meta-analysis. J Gambl Stud. 2019;35(2):415–45. doi:10.1007/s10899-018-09815-y.
   PubMed Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Schreiber LRN. Pharmacological treatments in pathological gambling. Br J Clin Pharmacol. 2014;77(2):375–81. doi:10.1111/j.1365-2125.2012.04457.x.
   PubMed Web of Science ®Google Scholar
• Johansen KGV, Tarp S, Astrup A, Lund H, Pagsberg AK, Christensen R. Harms associated with taking nalmefene for substance use and impulse control disorders: a systematic review and meta-analysis of randomised controlled trials. PLoS One. 2017;12(8):e0183821. doi:10.1371/journal.pone.0183821.
   PubMed Web of Science ®Google Scholar
• Kraus SW, Etuk R, Potenza MN. Current pharmacotherapy for gambling disorder: a systematic review. Expert Opin Pharmacother. 2020;21(3):287–96. doi:10.1080/14656566.2019.1702969.
   PubMed Web of Science ®Google Scholar
• Longuet Y, de Ternay J, Nourredine M, Jurek L, Angerville B, Derveaux A, Rolland B. Use of topiramate in the spectrum of addictive and eating disorders: a systematic review comparing treatment schemes, efficacy, and safety features. CNS Drugs. 2021;35(2):177–213. doi:10.1007/s40263-020-00780-y.
   PubMed Web of Science ®Google Scholar
• Mouaffak F, Leite C, Hamzaoui S, Benyamina A, Laqueille X, Kebir O. Naltrexone in the treatment of broadly defined behavioral addictions: a review and meta-analysis of randomized controlled trials. Eur Addict Res. 2017;23(4):204–10. doi:10.1159/000480539.
   PubMed Web of Science ®Google Scholar
• Di Nicola M, De Crescenzo F, D'Alò GL, Remondi C, Panaccione I, Moccia L, Molinaro M, Dattoli L, Lauriola A, Martinelli S, et al. Pharmacological and psychosocial treatment of adults with gambling disorder: a meta-review. J Addict Med. 2020;14(4):e15–e23. doi:10.1097/adm.0000000000000574.
   PubMed Web of Science ®Google Scholar
• Di Nicola M, De Risio L, Pettorruso M, Caselli G, De Crescenzo F, Swierkosz-Lenart K, Martinotti G, Camardese G, Di Giannantonio M, Janiri L, et al. Bipolar disorder and gambling disorder comorbidity: current evidence and implications for pharmacological treatment. J Affect Disord. 2014;167:285–98. doi:10.1016/j.jad.2014.06.023.
   PubMed Web of Science ®Google Scholar
• Pallesen S, Molde H, Arnestad HM, Laberg JC, Skutle A, Iversen E, Støylen IJ, Kvale G, Holsten F. Outcome of pharmacological treatments of pathological gambling: a review and meta-analysis. J Clin Psychopharmacol. 2007;27(4):357–64. doi:10.1097/jcp.013e3180dcc304d.
   PubMed Web of Science ®Google Scholar
• Victorri-Vigneau C, Spiers A, Caillet P, Bruneau M, Challet-Bouju G, Grall-Bronnec M. Ignace-Consortium Opioid antagonists for pharmacological treatment of gambling disorder: are they relevant? Curr Neuropharmacol. 2018;16(10):1418–32. doi:10.2174/1570159x15666170718144058.
   PubMed Web of Science ®Google Scholar
• Blank L, Baxter S, Woods HB, Goyder E. Interventions to reduce the public health burden of gambling-related harms: a mapping review. Lancet Public Health. 2021;6(1):e50–e63. doi:10.1016/s2468-2667%2820%2930230-9.
   PubMed Web of Science ®Google Scholar
• Hodgins DC, Stea JN, Grant JE. Gambling disorders. Lancet. 2011;378(9806):1874–84. doi:10.1016/s0140-6736(10)62185-x.
   PubMed Web of Science ®Google Scholar
• Łabuzek K, Beil S, Beil-Gawełczyk J, Gabryel B, Franik G, Okopień B. The latest achievements in the pharmacotherapy of gambling disorder. Pharmacol Rep. 2014;66(5):811–20. doi:10.1016/j.pharep.2014.05.003.
   PubMed Web of Science ®Google Scholar
• Lupi M, Martinotti G, Acciavatti T, Brunetti M, Santacroce R, Cinosi E, Iorio GD, Giannantonio MD, Pettorruso M, Nicola MD. Pharmacological treatments in gambling disorder: a qualitative review. Biomed Res Int. 2014;2014:537306. doi:10.1155/2014/537306.
   PubMed Web of Science ®Google Scholar
• Yip SW, Potenza MN. Treatment of gambling disorders. Curr Treat Options Psychiatry. 2014;1(2):189–203. doi:10.1007/s40501-014-0014-5.
   PubMedGoogle Scholar
• Castrén S, Mäkelä N, Haikola J, Salonen AH, Crystal R, Scheinin M, Alho H. Treating gambling disorder with as needed administration of intranasal naloxone: a pilot study to evaluate acceptability, feasibility and outcomes. BMJ Open. 2019;9(8):e023728. doi:10.1136/bmjopen-2018-023728.
   PubMed Web of Science ®Google Scholar
• de Brito AMC, de Almeida Pinto MG, Bronstein G, Carneiro E, Faertes D, Fukugawa V, Duque A, Vasconcellos F, Tavares H. Topiramate combined with cognitive restructuring for the treatment of gambling disorder: a two-center, randomized, double-blind clinical trial. J Gambl Stud. 2017;33(1):249–63. doi:10.1007/s10899-016-9620-z.
   PubMed Web of Science ®Google Scholar
• Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry. 2008a;69(5):783–9. doi:10.4088/jcp.v69n0511.
   PubMed Web of Science ®Google Scholar
• Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49(11):914–21. doi:10.1016/s0006-3223(01)01079-4.
   PubMed Web of Science ®Google Scholar
• Grant JE, Potenza MN, Hollander E, Cunningham-Williams R, Nurminen T, Smits G, Kallio A. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163(2):303–12. doi:10.1176/appi.ajp.163.2.303.
   PubMed Web of Science ®Google Scholar
• Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology. 2005;30(12):2254–62. doi:10.1038/sj.npp.1300811.
   PubMed Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Potenza MN, Hollander E, Kim SW. Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry. 2010;197(4):330–1. doi:10.1192/bjp.bp.110.078105.
   PubMed Web of Science ®Google Scholar
• Grant JE, Kim SW, Hollander E, Potenza MN. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology. 2008b;200(4):521–7. doi:10.1007/s00213-008-1235-3.
   PubMed Web of Science ®Google Scholar
• Reus VI, Fochtmann LJ, Bukstein O, Eyler AE, Hilty DM, Horvitz-Lennon M, Mahoney J, Pasic J, Weaver M, Wills CD, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175(1):86–90. doi:10.1176/appi.ajp.2017.1750101.
   PubMed Web of Science ®Google Scholar
• Grant JE, Potenza MN. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol. 2006;21(4):203–9. doi:10.1097/00004850-200607000-00002.
   PubMed Web of Science ®Google Scholar
• Saiz-Ruiz J, Blanco C, Ibáñez A, Masramon X, Gómez MM, Madrigal M, Díez T. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry. 2005;66(1):28–33. doi:10.4088/jcp.v66n0104.
   PubMed Web of Science ®Google Scholar
• Grant JE, Kim SW, Potenza MN, Blanco C, Ibanez A, Stevens L, Hektner JM, Zaninelli R. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int Clin Psychopharmacol. 2003;18(4):243–9. doi:10.1097/00004850-200307000-00007.
   PubMed Web of Science ®Google Scholar
• Kim SW, Grant JE, Adson DE, Shin YC, Zaninelli R. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry. 2002;63(6):501–7. doi:10.4088/jcp.v63n0606.
   PubMed Web of Science ®Google Scholar
• Blanco C, Petkova E, Ibáñez A, Sáiz-Ruiz J. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry. 2002;14(1):9–15. doi:10.1023/a:1015215809770.
   PubMedGoogle Scholar
• Hollander E, DeCaria CM, Finkell JN, Begaz T, Wong CM, Cartwright C. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry. 2000;47(9):813–7. doi:10.1016/s0006-3223(00)00241-9.
   PubMed Web of Science ®Google Scholar
• Black DW, Shaw M, Forbush KT, Allen J. An open-label trial of escitalopram in the treatment of pathological gambling. Clin Neuropharmacol. 2007;30(4):206–12. doi:10.1097/wnf.0b013e31803d357f.
   PubMed Web of Science ®Google Scholar
• Zimmerman M, Breen RB, Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry. 2002;63(1):44–8. doi:10.4088/jcp.v63n0109.
   PubMed Web of Science ®Google Scholar
• Patel R, Reiss P, Shetty H, Broadbent M, Stewart R, McGuire P, Taylor M. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. BMJ Open. 2015;5(12):e008341. doi:10.1136/bmjopen-2015-008341.
   PubMed Web of Science ®Google Scholar
• Hollander E, Pallanti S, Allen A, Sood E, Rossi NB. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry. 2005;162(1):137–45. doi:10.1176/appi.ajp.162.1.137.
   PubMed Web of Science ®Google Scholar
• Berlin HA, Braun A, Simeon D, Koran LM, Potenza MN, McElroy SL, Fong T, Pallanti S, Hollander E. A double-blind, placebo-controlled trial of topiramate for pathological gambling. World J Biol Psychiatry. 2013;14(2):121–8. doi:10.3109/15622975.2011.560964.
   PubMed Web of Science ®Google Scholar
• Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry. 2002;63(7):559–64. doi:10.4088/jcp.v63n0704.
   PubMed Web of Science ®Google Scholar